Oppenheimer Analysts Lift Earnings Estimates for Aptose Biosciences Inc. (TSE:APS)

Aptose Biosciences Inc. (TSE:APSGet Rating) (NASDAQ:APTO) – Equities research analysts at Oppenheimer boosted their FY2025 earnings estimates for Aptose Biosciences in a note issued to investors on Monday, May 9th. Oppenheimer analyst M. Biegler now anticipates that the biotechnology company will post earnings of $0.38 per share for the year, up from their prior forecast of $0.34.

Aptose Biosciences (TSE:APSGet Rating) (NASDAQ:APTO) last announced its quarterly earnings results on Tuesday, March 22nd. The biotechnology company reported C($0.34) EPS for the quarter, missing the consensus estimate of C($0.23) by C($0.11).

APS has been the topic of several other reports. Cantor Fitzgerald reissued an “overweight” rating on shares of Aptose Biosciences in a report on Friday, April 1st. Jonestrading reiterated a “buy” rating and issued a C$8.00 price target on shares of Aptose Biosciences in a report on Wednesday, March 23rd. Finally, HC Wainwright upped their price objective on Aptose Biosciences to C$12.00 and gave the stock a “buy” rating in a research note on Wednesday, March 23rd.

TSE:APS opened at C$1.38 on Wednesday. The firm has a 50-day simple moving average of C$1.53 and a 200-day simple moving average of C$1.92. Aptose Biosciences has a one year low of C$1.30 and a one year high of C$6.98. The firm has a market cap of C$127.28 million and a P/E ratio of -1.46. The company has a debt-to-equity ratio of 0.77, a quick ratio of 9.68 and a current ratio of 10.00.

Aptose Biosciences Company Profile (Get Rating)

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.

Featured Stories

Earnings History and Estimates for Aptose Biosciences (TSE:APS)

Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.